Pancreatic islet transcription factor and uses thereof

• US 7,405,289 B2
• Filed: 11/13/2003
• Issued: 07/29/2008
• Est. Priority Date: 11/13/2002
• Status: Expired due to Fees

• Current Assignee: CymaBay Therapeutics Inc.
• Original Assignee: Metabolix Incorporated
• Inventors: Johnson, Jeffrey D., Palma, John F., Blume, John E., Schweitzer, Anthony C.
• Primary Examiner(s): Benzion; Gary
• Assistant Examiner(s): MUMMERT, STEPHANIE KANE
• Application Number:
  US10/533,593
• Publication Number:
  US 20060264611A1
• Time in Patent Office: 1,720 Days
• Field of Search: None
• US Class Current: 536/23.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes.

Claims

1. An isolated nucleic acid encoding an IC-RFX polypeptide comprising SEQ ID NO:

2.

2. The nucleic acid of claim 1, wherein the nucleic acid comprises SEQ ID NO:

1.

4. An expression cassette comprising a promoter operably linked to the nucleic acid of claim 1 or claim 3.

5. An isolated host cell transfected with the nucleic acid of claim 1 or claim 3.

6. The host cell of claim 5, wherein the cell is a pancreatic islet cell.

7. The host cell of claim 6, wherein the cell is an islet β

-cell.

3. An isolated nucleic acid encoding a polypeptide comprising in the following order:

a proline/glutamine rich domain, an RFX DNA binding domain (SEQ ID NO;

4), an RFX B domain (SEQ ID NO;

5), an RFX C domain (SEQ ID NO;

6), a dimerization domain (SEQ ID NO;

7) and a serine/threonine domain.

8. A method of detecting a polynucleotide in a subject, the method comprising

detecting in a sample from the subject a polynucleotide encoding a polypeptide comprising in the following order:

a proline/glutamine rich domain, an RFX DNA binding domain (SEQ ID NO;

4), an RFX B domain (SEQ ID NO;

5), an RFX C domain (SEQ ID NO;

6), a dimerization domain (SEQ ID NO;

7) and a serine/threonine domain.

9. The method of claim 8, wherein the polynucleotide is detected by hybridization.

10. The method of claim 8, wherein the polynucleotide is detected by amplification of the polynucleotide.

11. The method of claim 8, wherein the nucleotide sequence of the polynucleotide is determined.

12. A method of introducing an expression cassette into an isolated cell, the method comprising,

introducing into the cell an expression cassette comprising a promoter operably linked to a polynucleotide encoding a polypeptide, the polypeptide comprising in the following order:

a proline/glutamine rich domain, an RFX DNA binding domain (SEQ ID NO;

4), an RFX B domain (SEQ ID NO;

5), an FRX C domain (SEQ ID NO;

6), a dimerization domain (SEQ ID NO;

7) and a serine/threonine domain.

13. The method of claim 12, wherein the polypeptide comprises SEQ ID NO:

2.

14. The method of claim 12, wherein the polynucleotide comprises SEQ ID NO:

1.

15. The method of claim 12, wherein the cell is a pancreatic islet cell.

16. The method of claim 12, wherein the cell is an islet β

-cell.